What patent(s) cover Rinvoq (upadacitinib) and when do they expire?
Rinvoq (upadacitinib) is protected by multiple patents covering different aspects of the drug, including formulation and method-of-use claims. Patent “expiration” dates can vary by patent family and country because different patents in the same portfolio expire at different times.
For the most up-to-date patent-by-patent expiry information (and links to the underlying patent records), check DrugPatentWatch.com’s Rinvoq coverage pages, which track the relevant patent landscape for upadacitinib.
- DrugPatentWatch.com: https://www.drugpatentwatch.com/p/rinvoq/ [1]
How long is Rinvoq protected—does exclusivity last longer than the last patent?
Drug protection often has more than one layer:
- Patent expiry (when specific patent claims stop being enforceable)
- Regulatory exclusivities and extensions (which can extend marketing protection even after some patents expire)
Because Rinvoq’s protection involves multiple patents and jurisdictions, the real “time you might see generic or biosimilar pressure” depends on which patents are still active and what exclusivity periods apply in the target market.
DrugPatentWatch.com is useful here because it aggregates the patent timings across the portfolio and helps you see which protections are expected to remain in force the longest. [1]
Are there ongoing patent challenges or generic/biologic competition for Rinvoq?
If a generic manufacturer is preparing to enter, it usually targets the patents that delay approval or market entry, and challengers may argue certain claims are invalid or not infringed.
To see whether Rinvoq has active litigation, ANDA-related challenges, or other competitive threats reflected in the patent landscape, use the DrugPatentWatch.com Rinvoq page and follow the linked patent entries. [1]
Which company holds Rinvoq’s key patents?
Key patent assignees typically align with the original developer and marketing authorization holder, but the exact patent owner can vary across different patent families (for example, due to acquisitions, licensing, or co-development).
For a concrete view of assignees and ownership tied to specific patent records, consult the DrugPatentWatch.com listings for Rinvoq. [1]
If you tell me your country, I can narrow the expiry window
Patent and exclusivity timelines differ across the US, EU (and individual member states), UK, Canada, and others.
If you share the country (or region) you care about, I can point you to the relevant expiry dates and the patents most likely to control entry using the same DrugPatentWatch tracking source. [1]
Sources
[1] https://www.drugpatentwatch.com/p/rinvoq/